AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24306710 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic Surgery Skill Evaluation Tool (pass-fail examination)
Number of subjects: 30
Study 24306710 — intervention group
Group type: EXPERIMENTAL
Intervention: Logging more than eighty arthroscopic cases or performing more than thirty-five arthroscopic knee cases
Number of subjects: 30
Study 24306710 — intervention group
Group type: EXPERIMENTAL
Intervention: Interclass correlation coefficient
Number of subjects: 30
Study 21278321 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational intervention group
Number of subjects: 245
Study 21278321 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 245
Study 19278844 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-calorie diet (VLCD) and weight maintenance (WM) with 120mg orlistat
Number of subjects: 35
Study 19278844 — intervention group
Group type: COMPARATOR
Intervention: Placebo during weight maintenance (WM)
Number of subjects: 35
Study 16903597 — intervention group
Group type: EXPERIMENTAL
Intervention: Scraping therapy and warming acupuncture-moxibustion
Number of subjects: 100
Study 16903597 — intervention group
Group type: COMPARATOR
Intervention: Simple acupuncture (Control)
Number of subjects: 100
Study 15023755 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel node biopsy (SNB) followed by immediate axillary clearance (AC)
Number of subjects: 1000
Study 15023755 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel node biopsy (SNB) followed by axillary clearance only if the SNB specimen is positive
Number of subjects: 1000
Study 15023755 — intervention group
Group type: COMPARATOR
Intervention: Immediate axillary clearance (AC)
Number of subjects: 1000
Study 10892875 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted quantitation of CNV
Number of subjects: 5
Study 10892875 — intervention group
Group type: COMPARATOR
Intervention: Standard methods for CNV identification
Number of subjects: 5
Study 9196866 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast enhanced MRI assessment
Number of subjects: 31
Study 9196866 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiography (x-ray)
Number of subjects: 31
Study 2006357 — intervention group
Group type: EXPERIMENTAL
Intervention: Piecewise exponential survival model
Number of subjects: 0
Study 2006357 — intervention group
Group type: COMPARATOR
Intervention: Piecewise exponential Cox model
Number of subjects: 0
Study 6315050 — intervention group
Group type: EXPERIMENTAL
Intervention: Wholemeal bread (phytate 2.2 mmol, non-starch polysaccharide 18.7 g)
Number of subjects: 6
Study 6315050 — intervention group
Group type: EXPERIMENTAL
Intervention: Brown bread (phytate 2.1 mmol, non-starch polysaccharide 10.9 g)
Number of subjects: 6
Study 6315050 — intervention group
Group type: EXPERIMENTAL
Intervention: White bread (phytate 2.3 mmol, non-starch polysaccharide 3.3 g)
Number of subjects: 6
Study 31092142 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS
Number of subjects: 26
Study 29428473 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesorectal excision alone
Number of subjects: 0
Study 29428473 — intervention group
Group type: COMPARATOR
Intervention: Mesorectal excision with lateral lymph node dissection
Number of subjects: 0
Study 29428473 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood loss ≥500 mL
Number of subjects: 0
Study 29428473 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor location in lower rectum
Number of subjects: 0
Study 26374448 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain (5% of body weight by 8 weeks of overfeeding)
Number of subjects: 44
Study 26374448 — intervention group
Group type: COMPARATOR
Intervention: Weight maintenance (control group)
Number of subjects: 44
Study 26374448 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin (in vitro experiments)
Number of subjects: 44
Study 26374448 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin antagonist (in vitro experiments)
Number of subjects: 44
Study 26374448 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipose tissue from normal-weight participants
Number of subjects: 44
Study 26374448 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipose tissue from obese participants
Number of subjects: 44
Study 26374448 — intervention group
Group type: EXPERIMENTAL
Intervention: Caveolin-1 expression in obese subjects
Number of subjects: 44
Study 25259469 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometrics (PG)
Number of subjects: 30
Study 25259469 — intervention group
Group type: COMPARATOR
Intervention: Combined training (CG)
Number of subjects: 30
Study 25259469 — intervention group
Group type: EXPERIMENTAL
Intervention: In-water-specific strength (WSG)
Number of subjects: 30
Study 22269592 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive-affect induction and self-affirmation (PA)
Number of subjects: 256
Study 22269592 — intervention group
Group type: COMPARATOR
Intervention: Patient education (PE)
Number of subjects: 256
Study 20169360 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH plus moderate intensity resistance training (DASH-RT)
Number of subjects: 27
Study 20169360 — intervention group
Group type: COMPARATOR
Intervention: DASH (control group)
Number of subjects: 27
Study 19180337 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillating positive expiratory pressure maneuvers followed by forced expiratory technique sequences with inhaled hypertonic saline (3%, 4% or 5%) in asthma patients (A/I)
Number of subjects: 26
Study 19180337 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillating positive expiratory pressure maneuvers followed by forced expiratory technique sequences with inhaled hypertonic saline (3%, 4% or 5%) in COPD patients (C/I)
Number of subjects: 26
Study 19180337 — intervention group
Group type: COMPARATOR
Intervention: Standard induced sputum protocol in asthma patients (A/C)
Number of subjects: 26
Study 19180337 — intervention group
Group type: COMPARATOR
Intervention: Standard induced sputum protocol in COPD patients (C/C)
Number of subjects: 26
Study 15736159 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysport (500 units)
Number of subjects: 80
Study 15736159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 12462513 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpharmacological treatment (vagal tone increase)
Number of subjects: 16
Study 12462513 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpharmacological treatment (little change in vagal tone)
Number of subjects: 16
Study 10690132 — intervention group
Group type: EXPERIMENTAL
Intervention: Omitting ACE inhibitor medication before surgery
Number of subjects: 40
Study 10690132 — intervention group
Group type: COMPARATOR
Intervention: Continuing ACE inhibitor medication before surgery
Number of subjects: 40
Study 9229859 — intervention group
Group type: EXPERIMENTAL
Intervention: Free gamma-aminobutyric acid and other neuroactive amino acids in cerebrospinal fluid (CSF)
Number of subjects: 64
Study 1984377 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg epidural morphine with 3 mL of normal saline (group 1)
Number of subjects: 30
Study 1984377 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg epidural morphine with 1 mg butorphanol and 2 mL of normal saline (group 2)
Number of subjects: 30
Study 1984377 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg epidural morphine with 3 mg butorphanol (group 3)
Number of subjects: 30
Study 330287 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefenamic acid
Number of subjects: 40
Study 330287 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 40
Study 30414785 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (treadmill at 60% of maximum volume of oxygen utilization)
Number of subjects: 10
Study 30414785 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (8 to 12 repetitions of 5 upper and lower body exercises at 60% to 80% of 1 repetition maximum)
Number of subjects: 10
Study 30414785 — intervention group
Group type: COMPARATOR
Intervention: No exercise (control)
Number of subjects: 10
Study 28181773 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitbit Charge HR (FIT)
Number of subjects: 17
Study 28181773 — intervention group
Group type: COMPARATOR
Intervention: Pedometer (PED)
Number of subjects: 17
Study 25087057 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (75 mcg/kg) administered after cardiopulmonary bypass
Number of subjects: 62
Study 25087057 — intervention group
Group type: EXPERIMENTAL
Intervention: Volatile anesthesia
Number of subjects: 62
Study 25087057 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative QTc
Number of subjects: 62
Study 23474908 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor with low-dose acetylsalicylic acid (ASA) (≤150 mg)
Number of subjects: 0
Study 23474908 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel with low-dose acetylsalicylic acid (ASA) (≤150 mg)
Number of subjects: 0
Study 23474908 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0
Study 23474908 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0
Study 21704242 — intervention group
Group type: EXPERIMENTAL
Intervention: Etamicastat 100 mg single dose
Number of subjects: 25
Study 21704242 — intervention group
Group type: EXPERIMENTAL
Intervention: Etamicastat 100 mg/day for 7 days
Number of subjects: 25
Study 21704242 — intervention group
Group type: EXPERIMENTAL
Intervention: Etamicastat single dose
Number of subjects: 25
Study 21704242 — intervention group
Group type: EXPERIMENTAL
Intervention: Etamicastat steady state
Number of subjects: 25
Study 21704242 — intervention group
Group type: EXPERIMENTAL
Intervention: Etamicastat
Number of subjects: 25
Study 21704242 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 25
Study 19428083 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 600 mg/d orally for 3 months
Number of subjects: 120
Study 19428083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 22832975 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted surgery
Number of subjects: 100
Study 22832975 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 100
Study 15948098 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurements of N-terminal pro-brain natriuretic peptide (NT-proBNP)
Number of subjects: 0
Study 15948098 — intervention group
Group type: EXPERIMENTAL
Intervention: Provision of plasma BNP data
Number of subjects: 0
Study 15948098 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial measurements of NT-proBNP
Number of subjects: 0
Study 12841537 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (I)
Number of subjects: 25
Study 12841537 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH)
Number of subjects: 25
Study 12841537 — intervention group
Group type: EXPERIMENTAL
Intervention: PCO-like group
Number of subjects: 25
Study 12841537 — intervention group
Group type: EXPERIMENTAL
Intervention: MFO group
Number of subjects: 25
Study 10464870 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) in an inhaler containing hydrofluoroalkane (HFA) propellant, Qvar®
Number of subjects: 0
Study 8553087 — intervention group
Group type: EXPERIMENTAL
Intervention: Venous platelet count (VPC) in LPC
Number of subjects: 35
Study 8553087 — intervention group
Group type: EXPERIMENTAL
Intervention: Capillary platelet count (CPC) in LPC
Number of subjects: 35
Study 8553087 — intervention group
Group type: EXPERIMENTAL
Intervention: Venous platelet count (VPC) in NPC
Number of subjects: 35
Study 8553087 — intervention group
Group type: EXPERIMENTAL
Intervention: Capillary platelet count (CPC) in NPC
Number of subjects: 35
Study 8553087 — intervention group
Group type: EXPERIMENTAL
Intervention: Reproducibility of counts in LPC
Number of subjects: 35
Study 8553087 — intervention group
Group type: EXPERIMENTAL
Intervention: Reproducibility of counts in NPC
Number of subjects: 35
Study 8553087 — intervention group
Group type: COMPARATOR
Intervention: Overall comparison of VPC and CPC
Number of subjects: 35
Study 2693691 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxypropyl methylcellulose 2% (Adatocel)
Number of subjects: 0
Study 2693691 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid 1% (Healon)
Number of subjects: 0
Study 754379 — intervention group
Group type: EXPERIMENTAL
Intervention: E-Test
Number of subjects: 633
Study 754379 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter-Matching-Test
Number of subjects: 633
Study 12426514 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin 600 mg orally once daily for 5 days (phase 2)
Number of subjects: 10
Study 30071058 — intervention group
Group type: EXPERIMENTAL
Intervention: High-polluted area
Number of subjects: 0
Study 30071058 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-polluted area
Number of subjects: 0
Study 30071058 — intervention group
Group type: COMPARATOR
Intervention: Control area
Number of subjects: 0
Study 26876527 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-Oriented Training (TOT) with EMG-stimulation for 30 minutes per day, 5 days per week, for 4 weeks
Number of subjects: 20
Study 26876527 — intervention group
Group type: COMPARATOR
Intervention: EMG-stimulation for 20 minutes per day, 5 days per week, for 4 weeks
Number of subjects: 20
Study 23904065 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hydrocortisone (11 infants)
Number of subjects: 22
Study 23904065 — intervention group
Group type: COMPARATOR
Intervention: Placebo (11 infants)
Number of subjects: 22
Study 23276234 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support + treatment as usual
Number of subjects: 41
Study 23276234 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 41
Study 20189226 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (2 mg daily at night) along with diclofenac sodium 50 mg
Number of subjects: 65
Study 20189226 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium 50 mg
Number of subjects: 65
Study 18080951 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated-sprint training group (RSG, 3 x 6 maximal shuttle sprints of 40 m)
Number of subjects: 42
Study 18080951 — intervention group
Group type: COMPARATOR
Intervention: Interval training group (ITG, 4 x 4 min running at 90 - 95 % of HRmax)
Number of subjects: 42
Study 18080951 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study 16146478 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular injection of bupivacaine (20 ml of 2.5 mg/ml) 30 min before skin incision
Number of subjects: 40
Study 16146478 — intervention group
Group type: COMPARATOR
Intervention: Post-operative administration of bupivacaine (20 ml of 2.5 mg/ml) after skin closure
Number of subjects: 40
Study 12182256 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate 1%/benzoyl peroxide 5% gel formulation
Number of subjects: 79
Study 12182256 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin 1% gel (monotherapy)
Number of subjects: 79
Study 10202871 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of clomiphene citrate on days 1-5 and placebo on days 5-9
Number of subjects: 23
Study 10202871 — intervention group
Group type: COMPARATOR
Intervention: Placebo on days 1-5 and clomiphene citrate on days 5-9
Number of subjects: 23
Study 8539022 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapiprazole 0.5% ophthalmic solution
Number of subjects: 90
Study 8539022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 2222553 — intervention group
Group type: COMPARATOR
Intervention: Placebo formulations (i.v. solution; p.o. solution; p.o. solid forms)
Number of subjects: 0
Study 2222553 — intervention group
Group type: COMPARATOR
Intervention: H1-antagonist positive control
Number of subjects: 0
Study 750663 — intervention group
Group type: EXPERIMENTAL
Intervention: Irregular temporal pulse patterns
Number of subjects: 0
Study 750663 — intervention group
Group type: COMPARATOR
Intervention: Regular temporal pulse patterns
Number of subjects: 0
Study 30471795 — intervention group
Group type: EXPERIMENTAL
Intervention: Andalusian aged wine (AAW)
Number of subjects: 41
Study 30471795 — intervention group
Group type: EXPERIMENTAL
Intervention: gin
Number of subjects: 41
Study 28274900 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (Group B)
Number of subjects: 748
Study 28274900 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin, tryptophan, and vitamin B6 (Group C)
Number of subjects: 748
Study 28274900 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group A)
Number of subjects: 748
Study 25592855 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m2)
Number of subjects: 30
Study 25592855 — intervention group
Group type: COMPARATOR
Intervention: Control (Prednisone alone)
Number of subjects: 30
Study 23488984 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical evacuation
Number of subjects: 180
Study 23488984 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical evacuation
Number of subjects: 180
Study 23488984 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 180
Study 21525521 — intervention group
Group type: EXPERIMENTAL
Intervention: Early screening for suicidal ideation
Number of subjects: 443
Study 21525521 — intervention group
Group type: COMPARATOR
Intervention: Delayed screening (control)
Number of subjects: 443
Study 19210298 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR 30 mg
Number of subjects: 445
Study 19210298 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR 60 mg
Number of subjects: 445
Study 19210298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 445
Study 16626426 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine diphosphate
Number of subjects: 34
Study 16626426 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 34
Study 12972527 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQOL) evaluation in treatment arms
Number of subjects: 0
Study 12972527 — intervention group
Group type: COMPARATOR
Intervention: Traditional clinical endpoints
Number of subjects: 0
Study 12972527 — intervention group
Group type: COMPARATOR
Intervention: Overall survival
Number of subjects: 0
Study 11096166 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab plus methotrexate
Number of subjects: 428
Study 11096166 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate alone
Number of subjects: 428
Study 8924098 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-midwifery care
Number of subjects: 194
Study 8924098 — intervention group
Group type: COMPARATOR
Intervention: Standard care (physician group)
Number of subjects: 194
Study 1560166 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fish oil supplementation (3.2 gm/day of eicosapentaenoic acid and 2.2 gm/day of docosahexaenoic acid) for 10 weeks
Number of subjects: 16
Study 1560166 — intervention group
Group type: COMPARATOR
Intervention: Placebo olive oil for 10 weeks
Number of subjects: 16
Study 1560166 — intervention group
Group type: EXPERIMENTAL
Intervention: Both fish oil and placebo
Number of subjects: 16
Study 4062052 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% lidocaine plus decongestant
Number of subjects: 10
Study 4062052 — intervention group
Group type: COMPARATOR
Intervention: Placebo (decongestant plus saline)
Number of subjects: 10
Study 30809788 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic screening with chromoendoscopy
Number of subjects: 0
Study 30809788 — intervention group
Group type: COMPARATOR
Intervention: Conventional screening (protocol-driven costs excluded)
Number of subjects: 0
Study 30809788 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated 10-year screening project
Number of subjects: 0
Study 30466597 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate re-supply treatment
Number of subjects: 0
Study 30466597 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate starvation treatment
Number of subjects: 0
Study 30466597 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate treatments (combined starvation and re-supply)
Number of subjects: 0
Study 30466597 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation of differentially expressed genes
Number of subjects: 0
Study 27044367 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic clinical decision‐support tool
Number of subjects: 3000
Study 27044367 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 3000
Study 25047415 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiplex nested PCR
Number of subjects: 54
Study 25047415 — intervention group
Group type: COMPARATOR
Intervention: Blood cultures
Number of subjects: 54
Study 22154338 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report measures, Behavioral Approach Test (BAT), physiological reactivity
Number of subjects: 144
Study 22154338 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Approach Test (BAT)
Number of subjects: 144
Study 22154338 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender role orientation (instrumentality)
Number of subjects: 144
Study 20202235 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular diclofenac 75 mg at the end of the operation followed by 75 mg for 24 hours (150 mg/24 h)
Number of subjects: 50
Study 20202235 — intervention group
Group type: COMPARATOR
Intervention: Intravenous paracetamol 1g/100 mL twice daily as postoperative analgesia
Number of subjects: 50
Study 18018837 — intervention group
Group type: COMPARATOR
Intervention: Halothane 1 ml, Isoflurane 1.5 ml, Sevoflurane 2.7 ml (experiment 1)
Number of subjects: 70
Study 18018837 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane 2, 4, and 6 ml (experiment 2)
Number of subjects: 70
Study 18018837 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane 5 ml (experiment 3)
Number of subjects: 70
Study 16170943 — intervention group
Group type: EXPERIMENTAL
Intervention: Time tunnel display
Number of subjects: 0
Study 16170943 — intervention group
Group type: COMPARATOR
Intervention: Baseline configural display
Number of subjects: 0
Study 16170943 — intervention group
Group type: COMPARATOR
Intervention: Trend display
Number of subjects: 0
Study 12038495 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of 4 spelling errors in a short essay
Number of subjects: 0
Study 12038495 — intervention group
Group type: EXPERIMENTAL
Intervention: Large number of spelling errors in a short essay
Number of subjects: 0